Emergence of SARS-CoV-2 Omicron (B. 1.1. 529) variant, salient features, high global health concerns and strategies to counter it amid ongoing COVID-19 pandemic

R Khandia, S Singhal, T Alqahtani, MA Kamal… - Environmental …, 2022 - Elsevier
Since the appearance in the late of December 2019, SARS-CoV-2 is rapidly evolving and
mutating continuously, giving rise to various variants with variable degrees of infectivity and …

[HTML][HTML] Paxlovid (Nirmatrelvir/Ritonavir): A new approach to Covid-19 therapy?

SMR Hashemian, A Sheida, M Taghizadieh… - Biomedicine & …, 2023 - Elsevier
Despite the need for novel, effective therapeutics for the COVID-19 pandemic, no curative
regimen is yet available, therefore patients are forced to rely on supportive and nonspecific …

Effectiveness of Paxlovid in reducing severe coronavirus disease 2019 and mortality in high-risk patients

R Najjar-Debbiny, N Gronich, G Weber… - Clinical Infectious …, 2023 - academic.oup.com
Background Paxlovid was granted an Emergency Use Authorization for the treatment of mild
to moderate coronavirus disease 2019 (COVID-19), based on the interim analysis of the …

[HTML][HTML] Omicron (B. 1.1. 529) variant of SARS‐CoV‐2: concerns, challenges, and recent updates

RK Mohapatra, R Tiwari, AK Sarangi… - Journal of medical …, 2022 - ncbi.nlm.nih.gov
Omicron (B.1.1.529) variant of SARS‐CoV‐2: Concerns, challenges, and recent updates -
PMC Back to Top Skip to main content NIH NLM Logo Access keys NCBI Homepage …

[HTML][HTML] The history, mechanism, and perspectives of nirmatrelvir (PF-07321332): an orally bioavailable main protease inhibitor used in combination with ritonavir to …

RP Joyce, VW Hu, J Wang - Medicinal Chemistry Research, 2022 - Springer
The rapid development of effective vaccines to combat the SARS-CoV-2 virus has been an
effective counter measure to decrease hospitalization and the mortality rate in many …

[HTML][HTML] Oral antiviral treatments for COVID-19: opportunities and challenges

L Rahmah, SO Abarikwu, AG Arero, M Essouma… - Pharmacological …, 2022 - Springer
The use of antiviral COVID-19 medications can successfully inhibit SARS-CoV-2 replication
and prevent disease progression to a more severe form. However, the timing of antiviral …

Targeting SARS-CoV-2 papain-like protease in the postvaccine era

AT Ton, M Pandey, JR Smith, F Ban… - Trends in …, 2022 - cell.com
While vaccines remain at the forefront of global healthcare responses, pioneering
therapeutics against SARS-CoV-2 are expected to fill the gaps for waning immunity. Rapid …

[HTML][HTML] Case report: sotrovimab, remdesivir and nirmatrelvir/ritonavir combination as salvage treatment option in two immunocompromised patients hospitalized for …

F Baldi, C Dentone, M Mikulska, D Fenoglio… - Frontiers in …, 2023 - frontiersin.org
COVID-19 in immunocompromised patients is difficult to treat. SARS-CoV-2 interaction with
the host immune system and the role of therapy still remains only partly understood. There …

[HTML][HTML] Drugs for COVID-19: An update

J Ceramella, D Iacopetta, MS Sinicropi, I Andreu… - Molecules, 2022 - mdpi.com
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was the seventh
known human coronavirus, and it was identified in Wuhan, Hubei province, China, in 2020. It …

[HTML][HTML] Structure genomics of SARS-CoV-2 and its Omicron variant: drug design templates for COVID-19

C Wu, W Yin, Y Jiang, HE Xu - Acta Pharmacologica Sinica, 2022 - nature.com
Abstract Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2), has brought an unprecedented public health crisis …